GSK plans to create giant UK biotech cluster
The site is already the UK’s largest cell and gene therapy cluster
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
746 stories · page 16 of 38
GlaxoSmithKline: This is what one leading Wall Street bank thinks of the CEO's plans
Morgan Stanley has provided little encouragement to the drug giant in its latest note
GlaxoSmithKline backs under-fire CEO and adds Parkinson's and Alzheimer's drugs
A deal struck with Alector will see the US-based company receive US$700mln in upfront payments and up to US$1.5bn in milestones
GlaxoSmithKline needs to review top management, activist investor Elliott Management says
The request comes amid debates around the competence of chief executive Emma Walmsley
GlaxoSmithKline quells market concerns for now but hard work yet to start
Chief executive Emma Walmsley presented her new strategy on Wednesday in what was seen as a 'make it or break it' event for her career
GlaxoSmithKline: Did CEO's revamp plan pass City muster? One leading bank has its say
Deutsche Bank upgraded its stock recommendation after the capital markets day
GSK on the rise after under fire chief executive unveils new five-year plan
The new strategy seemed to please investors, who are set to ask more questions on Wednesday afternoon's event
GlaxoSmithKline Investor Update: Live blog of Emma Walmsley statement
Proactive's live blog of GSK's media call with Emma Walmsley
Archive
Crunch time for GSK on Wednesday; Berkeley to report on London housing exodus
The pharma giant will kick off its eagerly anticipated investor day at the mid-point of the week
GlaxoSmithKline share price surge keeps Emma Walmsley’s head above water, but for how long?
The chief executive may be heading for an uncomfortable Capital Markets Day with activist investor Elliott leading the questioning
There’s deep value in GlaxoSmithKline, says City broker
The implied negative pipeline value is unwarranted as there are “gold star assets” with potential to fill the £3bn sales hole left by the upcoming dolutegravir patent expiry
GlaxoSmithKline snaps up promising cancer treatment ahead of crunch investor day
The announcement came ahead of the group's capital markets day next week
GlaxoSmithKline receives US emergency authorisation for COVID-19 treatment
The group has also announced the start of late-stage trials for the COVID-19 vaccine developed with Sanofi
GSK reports positive mid-trial results for second COVID-19 vaccine
The plant-based jab has been tested in combination with GSK's pandemic adjuvant
GSK and Sanofi look to catch up in vaccine race with booster doses
Approval may come a year later after their competitors, but the pair reckon there is a need for their candidate
GSK and Sanofi reveal positive trial results for COVID-19 vaccine
The pair are targeting approval by the end of the year
GlaxoSmithKline may not be doing so well compared to peers, City says
Chief executive Emma Walmsley expressed firm commitment to her plans after the spinoff on Wednesday, which may leave Elliott Management little leeway with its agenda
GlaxoSmithKline emerges as unlikely loser of COVID-19 pandemic – but will a return to normality be enough to sort out trouble?
Restrictions have hindered several of its programmes, but some issues may not resolve with the end of the pandemic
GlaxoSmithKline pins hopes on return to normality as quarterly turnover slides
The pharma giant will release more updates on the Consumer Healthcare spinoff and a new dividend policy in June
Frontier IP sees maturity spread across portfolio companies
The investment firm focuses on providing consultancy services to universities and other research organisations to help them commercialise any intellectual property arising from their research